PD-MIND

Parkinson disease with mild cognition impairment treated with nicotinic agonist drug
PD-MIND logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 13
Grant agreement number
820880

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
999 698
EFPIA in kind
1 000 000
Associated Partners
117 559
Other
14 352
Total Cost
2 131 609

Summary

Only 10% of compounds studied in the early stages of drug development make it into clinical trials, and of those, just 20% achieve regulatory approval. Nevertheless, the compounds that fall along the way can still prove useful in research and in some cases can be ‘repurposed’, i.e. used for the treatment of different diseases to the one for which they were originally developed. PD-MIND aims to repurpose a compound called AZD0328 as a treatment for Parkinson’s disease with mild cognitive impairment (PD-MCI). Recent trials have suggested that compounds like AZD0328 could improve cognition in people with Parkinson’s disease. Now, PD-MIND will carry out a randomised, placebo controlled study across multiple centres in different countries to see if this finding can be confirmed. Patients and other stakeholders will be involved from the start to ensure their viewpoints are taken into account in the design and execution of the trial. Repurposing drugs in this way has a number of advantages. Most notably, as a lot of work has already been carried out on the compounds, repurposing can deliver results much faster and for less money.

Participants Show participants on map

EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
Universities, research organisations, public bodies, non-profit groups
  • Helse Stavanger Hf, Stavanger, Norway
  • King'S College London, London, United Kingdom
  • Masarykova univerzita, Brno, Czech Republic
  • Technische Universitaet Dresden, Dresden, Germany
  • The University Of Exeter, Exeter, United Kingdom
  • Universita Degli Studi Gabriele D'Annunzio Di Chieti-Pescara, Chieti, Italy
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Stichting Lygature, Utrecht, Netherlands
Patient organisations
  • Norges Parkinsonforbund, Oslo, Norway
Associated partners
  • Parkinson'S Disease Society Of Theunited Kingdom Lbg, London, United Kingdom

CONTACT

Project coordinator
Dag ÅRSLAND
KING'S COLLEGE LONDON
daarsland[at]gmail.com